BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United StatesGlobeNewsWire • 06/09/20
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis MedicationGlobeNewsWire • 06/06/20
Long-term (48-week) Data Show Treatment with Berotralstat Provides Robust and Durable Reductions in HAE Attacks and Improvements in Quality of Life ScoresGlobeNewsWire • 06/06/20
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/01/20
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 04/27/20
BioCryst's Galidesivir: A Promising Candidate Drug In The Race To COVID-19 TreatmentSeeking Alpha • 04/16/20
Biocept To Begin COVID-19 Testing Wednesday, BioCryst, Athersys, Can-Fite To Research Potential Treatments In ClinicsBenzinga • 04/13/20